Ann: Appendix 4C and Quarterly Activities Report, page-8

Perhaps raise the idea of better communication, updates etc at the upcoming AGM on the 26/11...it may be something that would provide some solace to the longer term and ALL SH's. Agree with the previous comment about SP value with the consolidation, I do not necessarily agree with the consolidation, and feel that potential investors, particularly in the Biotech sector, are interested in the IP, proximity to commercialisation, point of differentiation of the product/s to competitors etc and most importantly who is running the show ie top level management. There has been some angst on the HC forum about the level of spending, staff appointments etc and I still believe that the value of these decisions should be judged 12 months on from the date of process. Then you can have more objective data to view, analyse and we should also be able to see who else in this space has made or lost ground as this sector often moves quickly at short notice. I remain hopeful but reserved in my decision as to whether the merger and running of the company has been good, mediocre, could have been better. The discussion here is very good and I appreciate the level of thought and analysis that some posters share, as always stay well, DYOR and GLTAH